Poly(ADP-ribose) Polymerase Inhibitors: all 983 studies that test it

Page 4 of 10. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.

• Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer PatientsActive, not recruitingNCT03737643Phase 3Results posted
• Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT03732820Phase 3Results posted
• Letermovir Treatment for Refractory or Resistant Cytomegalovirus InfectionCompletedNCT03728426Phase 2Results posted
• Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination DeficiencyTerminatedNCT03712930Phase 2Results posted
• The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)CompletedNCT03694262Phase 2Results posted
• Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneActive, not recruitingNCT03660826Phase 2Results posted
• Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompletedNCT03654833Phase 2Results posted
• Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the CervixTerminatedNCT03644342Phase 1/2Results posted
• Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum TherapyCompletedNCT03639935Phase 2Results posted
• A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid TumorsTerminatedNCT03637491Phase 1/2Results posted
• Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial CancerCompletedNCT03617679Phase 2Results posted
• A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerActive, not recruitingNCT03602859Phase 3Results posted
• Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 MutationsActive, not recruitingNCT03581292Phase 2Results posted
• Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in ChinaCompletedNCT03575065Phase 2Results posted
• Rucaparib and Nivolumab in Patients With Prostate or Endometrial CancerTerminatedNCT03572478Phase 1/2Results posted
• Olaparib Before Surgery in Treating Participants With Localized Prostate CancerTerminatedNCT03570476Phase 2Results posted
• Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid TumorsTerminatedNCT03565991Phase 2Results posted
• Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung CancerTerminatedNCT03559049Phase 1/2Results posted
• A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following ChemotherapyCompletedNCT03542175Phase 1Results posted
• Rucaparib in Nonmetastatic prOstAte With BRCAnessTerminatedNCT03533946Phase 2Results posted
• Olaparib in People With Malignant MesotheliomaCompletedNCT03531840Phase 2Results posted
• A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based ChemotherapyActive, not recruitingNCT03522246Phase 3Results posted
• Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate CancerCompletedNCT03516812Phase 2Results posted
• Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast CancerTerminatedNCT03499353Phase 2Results posted
• A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedNCT03498521Phase 2Results posted
• A Study of Niraparib as Single Agent in Participants With Advanced Solid TumorsCompletedNCT03497429Phase 1Results posted
• Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or EndometriumCompletedNCT03476798Phase 2Results posted
• A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)Active, not recruitingNCT03459846Phase 2Results posted
• Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene AlterationsCompletedNCT03448718Phase 2Results posted
• Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)CompletedNCT03443869Phase 3Results posted
• Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair DeficiencyTerminatedNCT03442556Phase 2Results posted
• Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric CancerCompletedNCT03427814Phase 2Results posted
• Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene MutationsCompletedNCT03413995Phase 2Results posted
• Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based ChemotherapyCompletedNCT03404960Phase 1/2Results posted
• Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer PatientsCompletedNCT03402841Phase 3Results posted
• Rucaparib in Patients With Locally Advanced or Metastatic Urothelial CarcinomaTerminatedNCT03397394Phase 2Results posted
• Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPCActive, not recruitingNCT03395197Phase 3Results posted
• Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerCompletedNCT03377556Phase 2Results posted
• Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment PatientsCompletedNCT03359850Phase 1Results posted
• A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid TumorsCompletedNCT03343054Phase 1Results posted
• An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate CancerCompletedNCT03338790Phase 2Results posted
• Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary CancerActive, not recruitingNCT03337087Phase 1/2Results posted
• Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruitingNCT03334617Phase 2Results posted
• Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid TumorsCompletedNCT03333915Phase 1/2Results posted
• Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast CancerCompletedNCT03329937Phase 1Results posted
• Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib CapsuleCompletedNCT03329001Phase 1Results posted
• A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyCompletedNCT03326193Phase 2Results posted
• Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone MetastasisActive, not recruitingNCT03317392Phase 1/2Results posted
• Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-OlaparibCompletedNCT03314740Phase 2Results posted
• Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042CompletedNCT03307785Phase 1Results posted
• Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT03289910Phase 2Results posted
• To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.CompletedNCT03286842Phase 3Results posted
• Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03233204Phase 2Results posted
• Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 MutationsActive, not recruitingNCT03212274Phase 2Results posted
• A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)CompletedNCT03207347Phase 2Results posted
• Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast CancerCompletedNCT03205761Phase 2Results posted
• Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)CompletedNCT03167619Phase 2Results posted
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results posted
• Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and BreastCompletedNCT03154281Phase 1Results posted
• Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT03150810Phase 1Results posted
• A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate CancerCompletedNCT03148795Phase 2Results posted
• Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based TherapyTerminatedNCT03140670Phase 2Results posted
• A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.CompletedNCT03106987Phase 3Results posted
• A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid TumorsCompletedNCT03077607Phase 1Results posted
• A Study of Talazoparib in Patients With Advanced Solid TumorsCompletedNCT03070548Phase 1Results posted
• Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & LymphomaCompletedNCT03061188Phase 1Results posted
• Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker AnalysisActive, not recruitingNCT03047135Phase 2Results posted
• A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid TumorsCompletedNCT03042910Phase 1Results posted
• Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast CancerCompletedNCT03025035Phase 2Results posted
• Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by SurgeryCompletedNCT03008278Phase 1/2Results posted
• An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)CompletedNCT02997176Phase 1Results posted
• An Open-Label Pharmacokinetics and Safety Study of TalazoparibCompletedNCT02997163Phase 1Results posted
• Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)CompletedNCT02987543Phase 3Results posted
• Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor StatusCompletedNCT02983799Phase 2Results posted
• A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyCompletedNCT02975934Phase 3Results posted
• Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent GlioblastomaActive, not recruitingNCT02974621Phase 2Results posted
• Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 MutationCompletedNCT02953457Phase 2Results posted
• A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyCompletedNCT02952534Phase 2Results posted
• A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung CancerCompletedNCT02937818Phase 2Results posted
• A Study to Test Combination Treatments in Participants With Advanced Gastric CancerCompletedNCT02935634Phase 2Results posted
• Open-Label Extension and Safety Study of TalazoparibCompletedNCT02921919Phase 2Results posted
• Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal CancerCompletedNCT02921256Phase 2Results posted
• Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial CancerActive, not recruitingNCT02912572Phase 2Results posted
• Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung CancerTerminatedNCT02899728Phase 2Results posted
• Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast CancerCompletedNCT02898207Phase 1Results posted
• FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic CancerCompletedNCT02890355Phase 2Results posted
• Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian CancerCompletedNCT02889900Phase 2Results posted
• Decitabine and Talazoparib in Untreated AML and R/R AMLCompletedNCT02878785Phase 1/2Results posted
• A Phase II Study Of Nivolumab/ Bevacizumab/RucaparibActive, not recruitingNCT02873962Phase 2Results posted
• ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsCompletedNCT02855944Phase 3Results posted
• An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair AnomaliesCompletedNCT02854436Phase 2Results posted
• A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue SarcomaCompletedNCT02787642Phase 1Results posted
• Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung CancerTerminatedNCT02769962Phase 1/2Results posted
• Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid TumorsCompletedNCT02723864Phase 1Results posted
• Olaparib in Treating Patients With Stage IV Pancreatic CancerCompletedNCT02677038Phase 2Results posted
• The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid TumorsCompletedNCT02660034Phase 1Results posted
• Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian CancerCompletedNCT02657889Phase 1/2Results posted
• A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyActive, not recruitingNCT02655016Phase 3Results posted
• Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain MetastasesCompletedNCT02595905Phase 2Results posted
• A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast CancerTerminatedNCT02561832Phase 1Results posted

← Poly(ADP-ribose) Polymerase Inhibitors overview